ACC 2022: An Embarrassment of Riches - Updated Guideline Recommendat…

ACC 2022 Conference Coverage

P. Heidenreich

ACC 2023: SGLT2i Use - Dos and Don'ts

ACC 2023 Conference Coverage

A. Armbruster

Which Diuretic(s) Are Best in HF? Update Based on Recent Clinical Tr…

MUSC Cardiology

R. Mentz

SGLT2 Inhibitors: For Heart Failure, Diabetes, and Renal Disease

Rita Jermyn

AHA 2022: Torsemide Comparison With Furosemide for Management of Hea…

AHA 2022 Conference Coverage

R. Mentz

2021 ADA Highlights: Heart Failure With Reduced Ejection Fraction - …

Michelle Kittleson

Management of Heart Failure

Obafemi Awolowo University

O. A. Akinyele

ECG Interpretation: Everything You Need to Know to Understand and In…

Houston Methodist DeBakey Heart and Vascular Center

A. Dave

EHRA 2024: Ongoing Clinical Investigations with Cardiac Contractilit…

CCM® Therapy

N. Varma

EHRA 2024: Real-World Experience with Cardiac Contractility Modulati…

CCM® Therapy

J. Kuschyk

EHRA 2024: Cardiac Contractility Modulation: Innovative Therapy for …

CCM® Therapy

V. Reddy, N. Varma, K. Kuck, J. Kuschyk, N. Aspromonte

HFpEF or Amyloidosis? The Right Therapies for Right Patients

Scripps Health

M. Kittleson

Donation After Cardiac Death: A New Paradigm for Organ Donation in H…

Cedars Sinai

P. Catarino

Classification, Diagnosis and Management of Pulmonary Hypertension: …

Icahn School of Medicine at Mount Sinai

R. Benza

EHRA 2024: Unmet Medical Needs in Heart Failure Management: Can Devi…

CCM® Therapy

N. Aspromonte

The Best of AHA23 for the Primary Care Doctor

Cecilia Bahit

EHRA 2024: Cardiac Contractility Modulation: Innovation Therapy for …

CCM® Therapy

K. Kuck, J. Kuschyk, V. Reddy, N. Aspromonte, N. Varma

Hot Topics in Heart Failure ACC.22

ACC 2022 Conference Coverage

N. Ibrahim

Weight Loss as Treatment for HFpEF: An Update on Drugs and Procedures

MUSC Cardiology

S. Litwin